Oppenhoff advises AddLife on acquisition of BioCat

Oppenhoff has advised the Swedish listed life science company AddLife AB on the acquisition of the BioCat Group.

AddLife AB, headquartered in Stockholm, acquires and operates market-leading companies in niche segments with offerings primarily focused on the healthcare sector – from research to medical care. The AddLife share has been listed on Nasdaq Stockholm, Large Cap, since 2016. With the acquisition of BioCat AddLife continues its expansion course in Europe.

BioCat, based in Heidelberg, Germany, is a specialized distributor of products and services to the life science research market and is primarily active in Germany, Austria and Switzerland. BioCat offers a wide portfolio of instruments and research reagents within the fast-growing fields of genomics, proteomics and cell biology to academia as well as to the pharma and biotech industry.

The Oppenhoff team, led by Myriam Baars-Schilling, included Sarah Scharf, Sebastian Gutmann (all Corporate/M&A), Dr Daniel Dohrn (Competition), Dr Fee Mäder (IP), Mareike Heesing (Public), Christian Saßenbach (Commercial), Ann Margret Herzhoff (Real Estate), Anja Dombrowsky, Jennifer Bold (both Employment) and Moritz Schmitz (Life Science Regulatory).

Oppenhoff regularly advises clients from the healthcare sector, most recently for example Shop Apotheke on the acquisition of Smartpatient.

Press contact: Julia Witte, Communications Consultant, T +49 221 2091-342, E [email protected] 

The full-service law firm Oppenhoff finds sector-specific solutions for groups, large owner-managed companies and financial investors. More than 100 lawyers advise in all important areas of business and tax law.

Back to list